According to IQVIATM sales data for the 12-month period ending February 2025, the Adderall Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market3 achieved annual sales of approximately $421.7 million.
The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
L-HPC was independently developed by Shin-Etsu Chemical as a disintegrant for tablets
AstraZeneca Pharma India discontinues manufacturing of Imdur
The products will be manufactured in Goa India and marketed & distributed in Australian markets
Alkem Medtech to acquire 100% stake of Bombay Ortho
USFDA inspection at Emcure Pharmaceuticals API facility
Subscribe To Our Newsletter & Stay Updated